CrossBridge Bio, a biotechnology company focused on dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, announced the closing of a $10 million seed financing led by TMC Venture Fund and CE-Ventures (the corporate venture capital platform of Crescent Enterprises), with participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.
Based on research from Dr. Kyoji Tsuchikama and Dr. Zhiqiang An of UTHealth Houston, CrossBridge Bio’s dual-payload ADC platform combines established and novel antibodies with various payload mechanisms of action, to develop a suite of ADC programs designed to offer distinct molecular properties, pharmacological actions, including payload synergy, and safety profiles for a range of cancer indications.
And the seed funding will be used for the development of the company’s lead program, CBB-120, a potential best-in-class TROP-2 dual-payload ADC for the treatment of solid tumors, and accelerate the expansion of its pipeline of novel ADC programs. And funds will be used to further derisk the company’s proprietary linker technology with dual-payload applications, a critical component of its ADC platform, to improve the safety and efficacy profiles of its current and future drug candidates.
In connection with the financing, William McKeon, President and CEO of the Texas Medical Center (TMC), and Damir Illich, Ph.D. Manager, Life Sciences of CE-Ventures, will join CrossBridge Bio’s board of directors, bringing extensive experience in healthcare and life sciences to support the company’s strategic growth.
KEY QUOTES:
“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need. Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments. With these funds, the seasoned team we have built at CrossBridge will advance CBB-120, the first development candidate in our portfolio, into preclinical non-GLP toxicology studies and lay the groundwork for its future clinical development.”
– Michael Torres, Ph.D., CEO of CrossBridge Bio
“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies. Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide, and we look forward to helping drive their development.”
– William McKeon
“CrossBridge Bio’s innovative platform and ambitious pipeline have positioned the company as a new leader in the ADC drug discovery and development arena. We are excited to support their efforts to translate their platform innovations into therapies that meaningfully impact patients’ lives, starting with CBB-120.”
– Dr. Illich
